Tirzepatide (brand name Mounjaro, research code LY3298176) is a synthetic peptide that activates both the GLP-1 and GIP hormone receptors at the same time. This dual action sets it apart from older single-receptor compounds. It is studied as a once-weekly injection for weight management and blood-sugar control.[6]

How does Tirzepatide work?

After you eat, your gut normally releases GLP-1 and GIP hormones to trigger insulin release, slow digestion, and signal fullness. Tirzepatide mimics both hormones simultaneously, producing a stronger combined effect on blood-sugar regulation and appetite suppression than activating either receptor alone.[6] Researchers believe the GIP component may also influence fat-tissue metabolism directly.[2]

What is Tirzepatide used for in research?

Research has focused on weight reduction in adults with obesity or overweight, glycemic control in type 2 diabetes, and — notably — prevention of progression from prediabetes to full type 2 diabetes. In one three-year trial, only 1.3% of tirzepatide-treated participants with prediabetes developed diabetes, versus 13.3% on placebo.[3]

How is Tirzepatide dosed in research studies?

Trials used once-weekly subcutaneous injections starting at low doses and escalating gradually over about 20 weeks to reduce stomach-related side effects.[3] Doses across studies ranged from 5 mg to 15 mg per week. Full details for each research context — including obesity and type 2 diabetes protocols — are in the dosage chart on this page.

How do you reconstitute Tirzepatide?

Clinical-trial tirzepatide comes pre-mixed in a pen; no reconstitution is needed. For dry research-grade powder, inject bacteriostatic water slowly down the inside wall of the vial, then swirl gently — never shake. Store the solution refrigerated (2–8 °C), away from light, and discard per your lab's protocols. Never use a cloudy or particulate-containing solution.

In published trials the most common side effects were gastrointestinal — nausea, vomiting, and diarrhea — mostly mild to moderate and concentrated in the dose-escalation phase.[3] No new safety signals were identified over three years of follow-up.[3] Gastrointestinal event rates were similar to those seen with semaglutide in a large real-world comparison.[1] This is research data, not medical advice.

Tirzepatide Dosage Chart, Protocol & Calculator

A dual incretin agonist researched for glycemic control and weight.

Objetivo	Dose	Frequência	Duração	Evidência	Fonte
Weight reduction in obesity (BMI ≥30 or ≥27 with complication, no diabetes) - low dose	5 mg	1x/week	72 weeks (including 20-week dose-escalation period)	Clinical	PMID 35658024
Weight reduction in obesity (BMI ≥30 or ≥27 with complication, no diabetes) - mid dose	10 mg	1x/week	72 weeks (including 20-week dose-escalation period)	Clinical	PMID 35658024
Weight reduction in obesity (BMI ≥30 or ≥27 with complication, no diabetes) - high dose	15 mg	1x/week	72 weeks (including 20-week dose-escalation period)	Clinical	PMID 35658024
Maintenance of weight reduction after initial tirzepatide lead-in (maximum tolerated dose)	10–15 mg	1x/week	52 weeks (after 36-week lead-in)	Clinical	PMID 38078870
Glycemic control in type 2 diabetes - low dose	5 mg	1x/week	40 weeks	Clinical	PMID 34170647
Glycemic control in type 2 diabetes - mid dose	10 mg	1x/week	40 weeks	Clinical	PMID 34170647
Glycemic control in type 2 diabetes - high dose	15 mg	1x/week	40 weeks	Clinical	PMID 34170647

What is Tirzepatide?

Tirzepatide (also known by the brand name Mounjaro, or by its research code LY3298176) is a synthetic peptide that mimics two natural gut hormones at once. Scientists classify it as a dual incretin agonist — meaning it activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. No other approved compound does both at the same time, which is what makes tirzepatide a subject of intense research interest in metabolism, weight regulation, and diabetes prevention.^[6]

It is administered as a once-weekly subcutaneous (under-the-skin) injection. As a research-use-only compound on this site, all dosing and outcome information below reflects published clinical trial data, not a prescription or treatment recommendation.

How Tirzepatide Works

Think of your gut as a chemical messaging system. Every time you eat, your intestines release hormones — including GLP-1 and GIP — that signal the pancreas to release insulin, tell the brain you are full, and slow stomach emptying. Tirzepatide is essentially a carefully engineered molecule that mimics both of those messenger molecules at once.^[6]

By hitting two receptors instead of one, tirzepatide produces stronger insulin release when blood sugar is high, a more powerful satiety (fullness) signal, and slower gastric emptying — all of which work together to lower blood glucose and reduce calorie intake. Because GIP receptors are also found in fat tissue, researchers believe the dual action may further influence how the body stores and burns fat, which helps explain the body-composition changes seen in trials.^[2]

What the Research Shows

Tirzepatide has been studied in a large clinical trial program called SURMOUNT (for obesity) and SURPASS (for type 2 diabetes). Here are the highlights in plain language:

Substantial weight loss in people without diabetes. In the SURMOUNT-1 trial, people with obesity or overweight who also had prediabetes lost an average of 12–20% of their body weight over roughly three years, depending on the dose, compared with about 1% in the placebo group.^[3]
Dramatically lower risk of developing type 2 diabetes. In the same prediabetes group, only 1.3% of tirzepatide participants progressed to type 2 diabetes over 176 weeks, versus 13.3% on placebo — a 93% relative risk reduction.^[3]
Body composition: mostly fat, not muscle. A substudy using DEXA scans found that about 75% of the weight lost with tirzepatide was fat mass and about 25% was lean (muscle) mass — roughly the same proportion seen with placebo, suggesting the weight lost follows a typical pattern rather than disproportionate muscle loss.^[2]
Effective across different populations. A randomized trial in Chinese adults with obesity found mean body-weight reductions of 13.6% (10 mg) and 17.5% (15 mg) at 52 weeks, with over 85% of participants losing at least 5% of their weight.^[4]
Outperforms semaglutide in real-world data. A large cohort study comparing tirzepatide and semaglutide in over 18,000 matched adults found that tirzepatide users were 76% more likely to achieve ≥5% weight loss, 2.5× more likely to achieve ≥10%, and more than 3× more likely to achieve ≥15% — with similar rates of gastrointestinal side effects between the two drugs.^[1]
Works in people with type 2 diabetes too. The SURMOUNT-2 trial showed significant weight loss and glycemic improvements in people who already had type 2 diabetes, a population where weight loss is typically harder to achieve.^[5]

What Tirzepatide Is Being Studied For

Weight reduction in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition^[3]
Glycemic (blood sugar) control in type 2 diabetes^[5]
Prevention of progression from prediabetes to type 2 diabetes^[3]
Long-term weight maintenance after initial weight loss^[3]
Body-composition changes (fat vs. lean mass) during weight loss^[2]
Metabolic outcomes in diverse ethnic populations^[4]

How Tirzepatide Is Dosed in Research

Research protocols use a gradual dose-escalation approach — starting low and stepping up every four weeks — to reduce gastrointestinal side effects.^[3] The specific doses and durations studied across obesity and type 2 diabetes trials are listed in the dosage chart on this page. If you want to calculate volumes or escalation schedules based on those reference doses, use the calculator also available here. All figures are for research reference only and should never be applied as personal medical guidance.

Mixing and Storing Tirzepatide

In clinical research settings, tirzepatide is supplied as a ready-to-use solution in a prefilled auto-injector pen — it does not require reconstitution (mixing with water) the way lyophilized (freeze-dried) peptides do. Research-grade vials of the raw peptide, however, may be supplied as a dry powder. In that context, standard peptide reconstitution practice applies: use bacteriostatic water (sterile water containing a small amount of benzyl alcohol as a preservative), inject the water slowly down the side of the vial rather than directly onto the powder, and swirl gently — never shake vigorously, as this can degrade the peptide. Once reconstituted, store at 2–8 °C (standard refrigerator temperature) and protect from light. Discard any unused solution according to your institution's protocols. Never use a solution that looks cloudy or contains visible particles.

Sources

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. — JAMA internal medicine, 2024. PMID 38976257.
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. — Diabetes, obesity & metabolism, 2025. PMID 39996356.
Tirzepatide for Obesity Treatment and Diabetes Prevention. — The New England journal of medicine, 2025. PMID 39536238.
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. — JAMA, 2024. PMID 38819983.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. — Lancet (London, England), 2023. PMID 37385275.
New Drug: Tirzepatide (Mounjaro(™)). — The Senior care pharmacist, 2023. PMID 36751934.

Tirzepatide Guia & Tabela de Dose